04:32 PM EDT, 05/13/2025 (MT Newswires) -- Exelixis ( EXEL ) reported Q1 non-GAAP net income late Tuesday of $0.62 per diluted share, up from $0.17 a year earlier.

Analysts polled by FactSet expected $0.44.

Revenue for the quarter ended March 31 was $555.4 million, up from $425.2 million a year earlier.

Analysts polled by FactSet expected $499.6 million.

For full-year 2025, the oncology company increased its revenue guidance to a range of $2.25 billion to $2.35 billion, up from its prior outlook of $2.15 billion to $2.25 billion. Analysts polled by FactSet are looking for $2.25 billion.

Exelixis ( EXEL ) shares were up more than 6% in Tuesday's after-market activity.

Price: 39.35, Change: +2.40, Percent Change: +6.50